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Biochemical and Genetic Analysis of ANK in Arthritis and Bone
Disease
Kyle A. Gurley, Richard J. Reimer, and David M. Kingsley
Mutations in the progressive ankylosis gene (Ank/ANKH) cause surprisingly different skeletal phenotypes in mice and
humans. In mice, recessive loss-of-function mutations cause arthritis, ectopic crystal formation, and joint fusion through-
out the body. In humans, some dominant mutations cause chondrocalcinosis, an adult-onset disease characterized by
the deposition of ectopic joint crystals. Other dominantmutations cause craniometaphyseal dysplasia, a childhooddisease
characterized by sclerosis of the skull and abnormal modeling of the long bones, with little or no joint pathology. Ank
encodes a multiple-pass transmembrane protein that regulates pyrophosphate levels inside and outside tissue culture
cells in vitro, but its mechanism of action is not yet clear, and conﬂicting models have been proposed to explain the
effects of the human mutations. Here, we test wild-type and mutant forms of ANK for radiolabeled pyrophosphate-
transport activity in frog oocytes. We also reconstruct two human mutations in a bacterial artiﬁcial chromosome and
test them in transgenic mice for rescue of the Ank null phenotype and for induction of new skeletal phenotypes. Wild-
type ANK stimulates saturable transport of pyrophosphate ions across the plasma membrane, with half maximal rates
attained at physiological levels of pyrophosphate. Chondrocalcinosis mutations retain apparently wild-type transport
activity and can rescue the joint-fusion phenotype of Ank null mice. Craniometaphyseal dysplasia mutations do not
transport pyrophosphate and cannot rescue the defects of Ank null mice. Furthermore, microcomputed tomography
revealed previously unappreciated phenotypes in Ank null mice that are reminiscent of craniometaphyseal dysplasia.
The combination of biochemical and genetic analyses presented here provides insight into how mutations in ANKH
cause human skeletal disease.
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Mineral deposition is a highly regulated process in verte-
brates and is normally conﬁned to the bony skeleton. Ex-
cess or ectopic mineral deposition occurs in a large frac-
tion of the elderly population and is a phenotype of many
speciﬁc diseases. Recent progress in both mouse and hu-
man genetics has identiﬁed a number of genes that play
key roles in controlling mineral deposition in body tis-
sues.1–17 Mutations in several of these genes affect the gen-
eration or degradation of pyrophosphate (PPi) and lead to
defects in crystal formation throughout the skeleton. At
low levels, PPi is a potent inhibitor of calcium phosphate
crystal formation.18,19 It is even used commercially to in-
hibit mineralization, including its use as an ingredient in
most forms of tartar-control toothpaste. In contrast, when
present at high levels, PPi itself can precipitate with cal-
cium ions to form an alternative type of crystal called
“calcium pyrophosphate dihydrate” (CPPD).20–22
ANKH (or themouse orthologAnk) encodes a novel 492-
aa multipass transmembrane protein (ANKH/ANK) that is
hypothesized to transport PPi ions across the plasmamem-
brane to the extracellular environment.3 The importance
of Ank was ﬁrst elucidated in mice when it was shown
that a spontaneous mutation called “progressive ankylo-
sis” (ank) causes hydroxyapatite—Ca5(PO4)3(OH)—min-
eral deposition in the articular cartilage and synovial
ﬂuid.3,15 Crystal deposition begins at age ∼3–4 wk and ul-
timately leads to immobility due to the complete fusion
of almost every joint in the body.23,24 The nonsense ank
mutation results in the C-terminal truncation of the ANK
protein by 53 aa.3 We recently reported that mice homo-
zygous for the Ank null allele (Anknull) exhibit the same
phenotype as do ank mice.25
The discovery of ANK and its role in joint maintenance
led to the discovery of mutations in ANKH that are as-
sociated with a variety of skeletal defects in humans.8,10,
11,17,26–31 Four dominant mutations in ANKH cause familial
chondrocalcinosis (CCAL2 [MIM 118600]), an adult-onset
mineral-deposition disease.10,17,30 Like ank mice, patients
with CCAL2 experience ectopic crystal deposition in the
articular cartilage and synovial ﬂuid. However, in contrast
to the hydroxyapatite crystals deposited in the joints of
young ankmice, the crystals found in the joints of patients
with CCAL2 are composed of CPPD and do not appear
until the 3rd or 4th decade of life. The familial CCAL2
mutations cluster at the N terminus of the ANKH protein,
and each results in a change of only 1–4 aa.
Six additional dominant mutations in ANKH were dis-
covered in studies of craniometaphyseal dysplasia (CMD
[MIM 123000]) in humans.8,11 CMD is a rare condition
characterized by hyperostosis and sclerosis of the skull,
together with ﬂaring and abnormal modeling of the me-
taphyses of the long bones. In striking contrast to the joint
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diseases caused by the recessive mouse ank mutation and
the dominant human CCAL2 mutations, patients with
CMD have normal joints. All of the CMDmutations affect
single amino acids and cluster in a small region of the
ANKH protein that is distinct from the region affected in
patients with CCAL2.
In addition to the protein-coding mutations that cause
CCAL2 and CMD, noncoding ANKH polymorphisms as-
sociate with ankylosing spondylitis, a devastating disease
that results in fusions of the spine, and with hand bone
size and geometry.26–29 Despite the clear involvement of
ANKH in numerous skeletal defects, very little is known
about how mutations in the ANKH protein affect its
function.
The ANK protein contains 8–12 predicted transmem-
brane helices and is present on the plasma membrane.3
Overexpression of Ank in tissue culture cells leads to an
increase in total levels of extracellular PPi.3,31 Conversely,
loss of ANK activity in mutant cells leads to a decrease in
extracellular PPi levels,3,32,33 which translates in vivo to in-
creased mineral formation in articular cartilage and joints.
The multiple-pass transmembrane sequence of the ANK
protein suggests that it may act directly as a PPi trans-
porter. However, all previous measurements of ANK func-
tion have relied on bulk PPi measurements from cells and
media after several days in culture. No experiments have
directly tested whether ANK stimulates the actual move-
ment of PPi across the plasma membrane.
It is also not clear whether the different human muta-
tions act by loss- or gain-of-functionmechanisms.Human
CCAL2 mutations may be weak hypermorphicmutations,
because they cause elevated levels of PPi in synovial ﬂuid
and predispose to deposition of CPPD crystals.10,34–36 How-
ever, two different groups tested the activity of these mu-
tant alleles by overexpression in tissue culture cells and
reported different results, which led to different conclu-
sions about their function.10,31 Importantly, this has led
some investigators to question whether the effect of ANK
on PPi levels is relevant to its role in human disease.31
HumanCMDmutations are interestingbecause theyclus-
ter in a small region of the ANKH protein and cause thick-
ening of bones without major effects on joints. Conﬂict-
ing models have been proposed about the possible effects
of these mutations on ANKH activity, with different groups
suggesting that the CMD alleles act as hypermorphic, hy-
pomorphic, or dominant negative mutations.8,11 No bio-
chemical measurements of the activity of CMD-mutant
proteins have been described. Finally, no in vivo assays
have been reported that examine the activity of the CCAL2
or CMD ANKH alleles in mice.
To better understand the normal function of the ANK
protein and its role in human disease, we used a combina-
tion of radiotracer ﬂux experiments and transgenic mice
to characterize the activity of wild-type and mutant ANK
proteins. The combined biochemical and genetic data con-
ﬁrm an important role for ANK in PPi transport and pro-
vide a model to explain how different types of mutations
in ANKH lead to human disease.
Material and Methods
Molecular Biology
The human ANKH and mouse ANK proteins are both 492 aa in
length and are 98% identical, differing at only 8 aa. All known
human alleles affect conserved amino acids. Variant alleles were
therefore introduced into the mouse Ank cDNA. The P5T base-
pair change was 13CrA. TheM48T base-pair changewas 143TrC.
The C331R base-pair change was 991TrC. The G389R base-pair
change was 1165GrA. For expression in Xenopus oocytes, cDNA
samples were subcloned from pCDNA3 into pOX, which con-
tains 5′ and 3′ UTR sequences from frog beta-globulin. Mutations
were introduced by PCR, and all constructs were conﬁrmed by
sequencing.
Expression of ANK in X. laevis Ooctyes
CappedmRNA (cRNA) was transcribed in vitro with T3 RNA poly-
merase (mMESSAGE mMACHINE kit [Ambion]) fromNotI-linear-
ized templates and was resuspended in nuclease-free water. Oo-
cytes were surgically collected from animals anesthetized under
0.17% tricaine and were incubated for 1 h, with shaking, in ND96
(in mM: 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, and 5 HEPES [pH
7.6]) and 2 mg/ml of collagenase. Healthy stage V and VI oocytes
were injected with 80 nl of RNase-free water or 8–16 ng of cRNA.
Healthy injected oocytes were given fresh ND96 daily and were
maintained at 18C before uptake studies were performed.
Membrane-Enriched Protein Lysates and Cell-Surface
Biotinylation
Proteins were isolated from healthy oocytes 2–9 d after injection.
Groups of 10–30 oocytes were homogenized in 500 ml ice-cold
hypotonic lysis buffer (15 mM tris [pH 6.8]) plus Complete Mini
protease inhibitors (Roche Applied Science). To remove yolk pro-
teins, the homogenate was mixed 1:1 with 1,1,2-trichloroﬂoro-
ethane (Sigma), was vortexed, and was centrifuged at for3,600 g
10 min at 4C. Membranes were pelleted by centrifugation and
were resuspended in 10–15 ml of lysis buffer with protease inhib-
itors. Protein concentration was determined by the method of
Lowry.
Cell-surface biotinylation experiments were performed 2 d after
injection. Pools of 15–20 healthy oocytes were labeled with 2mM
EZ-Link-Sulfo-NHS-LC-Biotin (Pierce Biotechnology), as per the
manufacturer’s instructions. After removal of yolk proteins from
the lysates, a 20-ml aliquot was collected for total protein. The
remaining lysates were incubated with streptavidin beads (Pierce)
for 1–8 h at 4C. Precipitated proteins were eluted in SDS loading
buffer at 55C–65C for 20 min.
Western Blots
Proteins were separated by 10% SDS-PAGE. The primary anti-
bodies were rabbit-aANK (Ab33) and mouse-aPDI (protein disul-
phide isomerase) (Stressgen Bioreagents). Immunoblotting and
detection of horseradish peroxidase–conjugated secondary anti-
bodies (Santa Cruz Biotechnology) by enhanced chemilumines-
cence (Amersham) were done according to manufacturers’ in-
structions. For surface-labeling experiments, the blots were probed
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with aANK, were stripped as recommended, and were reprobed
with aPDI.
PPi Uptake Assays
Uptake experiments were conducted at room temperature 2 d
after cRNA injection. Groups of 7–9 oocytes were washed in fresh
ND96 and were incubated in 120 ml of transport buffer (ND96
containing 33PPi [Perkin Elmer Custom Synthesis] to a ﬁnal spe-
ciﬁc activity of 50 Ci/mmol) at room temperature for 20 min,
unless otherwise indicated. Uptake was stopped by washing three
times in 2 ml of ice-cold ND96. Oocytes were lysed individually
in 150 ml of 10% SDS, and radioactive counts were determined
after adding 4ml of liquid scintillation ﬂuid. Each ﬁnal data point
was determined by removing the highest oocyte count and the
lowest oocyte count from each pool (7–9 oocytes) and averaging
the results from at least three independent experiments, each
from a separate batch of oocytes. Thin-layer chromatography
showed that no detectable hydrolysis of PPi to Pi occurred in
transport buffer incubated with oocytes during the time periods
used for PPi uptake assays (data not shown).
Generation of BAC Transgenic Mice
Using homologous recombination in Escherichia coli,37 we mod-
iﬁed a BAC that contains the Ank locus and was used elsewhere
as a transgene to rescue mutant ank animals.3 For both of the
AnkM48T and AnkG389R alleles, a tetracycline cassette was inserted
into the appropriate site and then was replaced with the intended
base-pair mutation.
The primers used to amplify the tetracycline cassette and in-
troduce homology armswere: forAnkM48T-tet, 5′-GGCCTTGAACC-
GGGGCATCGCTGCAGTCAAGGAGGATGCAGTAGAAGATCTA-
TGATTCCCTTTGTCAACAG-3′ (forward) and 5′-TCAGGGTGTG-
GAAGACGGCAGCGATGGCACCGGCCACCACCATGCAAGCTT-
ATGATGATGATGTGCTTAAAAAC-3′ (reverse); for AnkG389R-tet, 5′-
CACACCCTTCTCTCCTCAGTGACTGTGAGAGCTCATCTCACTA-
GATCTATGATTCCCTTTGTCAACAG-3′ ( forward) and 5′-CAGG-
TACGGCAGGACCACAAGGCTGGTGATGAGGACGATGATAAG-
CTTATGATGATGATGTGCTTAAAAAC-3′ (reverse). The template
used for the replacement amplicon was an Ank cDNA vector con-
taining the desired point mutation (see the “Molecular Biology”
section). The primers were: for AnkM48T, 5′-GCGGATCCGGCCTTG-
AACCGGGGCAT-3′ (forward) and 5′-GCGGATCCCAGGGTGTGG-
AAGACGGCA-3′ (reverse); for AnkG389R, 5′-GCGGATCCCACACCC-
TTCTCTCCTCAGTGACTGTGAGAGCTCATCTCACT-3′ (forward)
and 5′-CGCGGATCCCAGGTACGGCAGGACCACA-3′ (reverse).
Pulse-ﬁeld gel electrophoresis, DNA ﬁngerprinting, and PCR/
DNA sequencing were used to verify BAC integrity and to conﬁrm
that the appropriate changes were made. The modiﬁed BACs are
referred to in the text as “BAC-AnkM48T” and “BAC-AnkG389R.”
Circular BAC DNAs were dialyzed in microinjection buffer (10
mM Tris [pH 7.4] with 0.15 mM EDTA [pH 8.0]), were adjusted
to 1 ng/ml, and were injected into the pronuclei of fertilized eggs
from FVB/N or B6CBAF1/J mice by the Stanford Transgenic Fa-
cility. Transgenic founder mice were identiﬁed by PCR, with use
of BAC-speciﬁc primers 5′-CTATAGTGTCACCTAAATAGC-3′ (for-
ward) and 5′-GGTTCGCGTTGGCCGATT-3′ (reverse). Foundermice
generated on the hybrid background were ﬁrst bred to FVB/N
mice to introduce a polymorphic D15Mit180 allele near the Ank
locus that was used for genotyping in the rescue studies.
BAC-positive mice were crossed with /Anknull mice for 2 gen-
erations to produce F2 animals that were assessed for rescue and
were phenotyped. Genotyping primers for the Anknull allele at the
endogenous Ank locus were described elsewhere.25 The marker
D15Mit180 was used to genotype for rescue (5′-TTGCCATTGCAA-
TGCATG-3′ [forward] and 5′-GGTCAGCCATGAAAGCATAA-3′ [re-
verse]). All mice were on mixed backgrounds, including FVB/N,
CBA/J, C57BL/6, C3H/HeJ, and 129S1/SvImJ. All analyzed mice
were littermates and/or siblings from the same mating.
Veriﬁcation of Transgene Expression
To screen transgenic lines for expression of the introduced alleles,
RNA was collected from spleen, liver, and kidney, with use of the
RNAqueous-4-PCR kit (Ambion), and reverse transcription was
performed using random decamers. PCR primers for BAC-AnkM48T
were 5′-GGCCTTGAACCGGGGCAT-3′ (forward) and 5′-CAGCTC-
TGGGCCGCTCCTGT-3′ (reverse) and generated a 589-bp prod-
uct. RT-PCR products from /Anknull;BAC-AnkM48T animals were
directly sequenced, to detect transgene expression. The sequenc-
ing primer (5′-ACAGACTCATCCACATGATGC-3′) recognizes Ank
exon 3 and does not hybridize with the Anknull allele from the
endogenous locus. Therefore, the apparent ratio of endogenous
Ank transcripts to transgenic Ank transcripts was 1:1, which en-
abled the detection of transgene transcripts from the sequencing
chromatograms.
Primers for BAC-AnkG389R were 5′-TGGCTCTGATCCTGGCCACG-
3′ (forward) and 5′-CTTCTCTCATCTCTACGATGT-3′ (reverse) and
generated a 738-bp product. The wild-type product can be di-
gested with FokI into two bands, 435 bp and 303 bp. The G389R
allele eliminates this restriction site, and PCR products from this
allele are not digested with FokI.
Mouse Phenotyping
Mice were euthanized at age 6 wk, 6 mo, or 1.5 years. Knee anal-
ysis was performed using both AnkM48T lines that rescued the Ank
null phenotype. Skull and femur analysis was performed on two
of the four AnkG389R lines that expressed the transgene as assayed
by RT-PCR. Skulls, right forepaws, right hindpaws, and right legs
were ﬁxed in 10% buffered formalin, were rinsed in PBS, and
then were transferred to 70% ethanol for long-term storage at
4C. Forepaws, legs, and skulls were scanned and evaluated by
microCT (mCT) in 70% ethanol. mCT analysis was performedusing
a mCT-40 (ScanCo Medical) operated at a tube potential of 45 kV
and a tube current of 177mA, with use of a 0.30-s integrationwith
2# averaging. A threshold to distinguish bone from soft tissue
was empirically determined using wild-type specimens. Voxel sizes
were 8 mm3 for mouse forepaws, 16 mm3 for femurs, and 16 mm3
for skulls from mice sacriﬁced at age 6 wk and were 20 mm3 for
skulls from mice sacriﬁced at age 6 mo. All six F2 genotypes from
the cross shown in ﬁgure 3 were analyzed.
To assign thickness values for each point in the skull, ﬁles con-
taining the coordinates for all pixels of the skull were processed
as described elsewhere.38–40 In brief, for each pixel, the diameter
of the largest possible bone-containing sphere was calculated, and
each pixel was assigned a thickness value. This process generated
(1) a histogram of the number of pixels that were assigned to
each bin of thickness values and (2) a skull-thickness map that
shows the assigned thickness values in three-dimensional space.
For distal femurs, evaluation of cancellous bone in the meta-
physeal region was performed on 50 two-dimensional slices (800
mm), starting at the base of the growth plate and moving prox-
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Figure 1. ANK stimulation of PPi translocation across the plasma
membrane. A, Agarose gel of wild-type (WT) Ank and mutant ank
cRNAs, with western blot of membrane-enriched protein lysates
from Xenopus oocytes 3 d after cRNA injection. The cRNA appears
intact, and the ANK protein was detected. The mutant ank cRNA
encodes a truncated protein (E440X) that does not contain the C-
terminal epitope recognized by the ANK antibody and therefore
served as a control for antibody speciﬁcity. B, Time course of PPi
uptake by oocytes in transport buffer with 1 mM 33PPi. After sub-
tracting uptake by water-injected controls, the calculated rate of
ANK-dependent transport is fmol per oocyte per min1.54 0.04
( ). C, Rate of ANK-stimulated PPi transport as a function ofnp 3
substrate concentration. The transport rate was saturable, and the
apparent Km was mM after subtracting uptake by wa-1.33 0.59
ter-injected controls ( ). A single asterisk (*) indicatesnp 8 P !
; a double asterisk (**) indicates ; a triple asterisk (***).05 P ! .01
indicates .P ! .001
imally toward the diaphysis. The cortex of the metaphysis was
evaluated for the 20 most-proximal slices that were used for the
cancellous evaluation.
Statistics
Signiﬁcance was evaluated by t test versus control values or anal-
ysis of variance (ANOVA) with Bonferroni’s multiple-comparison
test. All statistics, including nonlinear and linear regression, were
performed using the Prism software package (Graphpad Software).
Data are presented as mean  SE.
Results
ANK-Stimulated PPi Flux across the Plasma Membrane
An X. laevis heterologous expression system was used to
test whether the ANK protein stimulates movement of PPi
across the plasma membrane. It is hypothesized that ANK
mediates transport of PPi out of cells, but we were unable
to directly measure PPi efﬂux from oocytes because of tech-
nical limitations. However, we were able to take advantage
of the bidirectionality of transport and instead measured
uptake, an approach that has proven successful in the char-
acterization of other transporters.41–48
Ank in vitro–transcribed cRNAwas injected intoXenopus
oocytes, which expressed the ANK protein within 2 d (ﬁg.
1A and data not shown). ANK-expressing oocytes were
incubated in 1 mM radiolabeled PPi for various amounts
of time and showed linear uptake over the course of 1 h
(ﬁg. 1B). After 10 min, uptake by ANK-expressing oocytes
was already 16.3-fold greater than uptake by water-in-
jected controls. Linear regression revealed an uptake rate
of fmol PPi per oocyte per min. This is equiv-1.54 0.04
alent to a turnover rate of PPi ions per62.57 0.067# 10
s per oocyte. Uptake was then measured at the 20-min
time point for a variety of PPi concentrations. Plotting
the rate of transport versus substrate concentration re-
vealed that the rate of ANK-dependent PPi uptake was
saturable with an apparent Michaelis-Menten constant
(Km) of mM (ﬁg. 1C).1.33 0.59
To assess whether the disease-causing Ank mutations af-
fect ANK-stimulated PPi-transport activity, oocytes were
injected with the appropriate cRNAs, and PPi ﬂux was
measured at near-saturating (7 mM) conditions. The tested
CCAL2 mutant proteins (P5T and M48T) displayed wild-
type levels of transport activity, and saturation curves re-
vealed that neither apparent Km was signiﬁcantly dif-
ferent from that measured in parallel for wild-type ANK
(ﬁg. 2A and 2B). In contrast, the ank truncation protein
(E440X) and both of the tested CMD mutant proteins
(C331R and G389R) showed little to no PPi-transport ac-
tivity (ﬁg. 2A). This was not due to mislocalization, since
surface biotinylation experiments conﬁrmed that, with the
exception of the truncated ank protein—which is missing
the epitope recognized by the anti-ANK antibody and
served as a control for antibody speciﬁcity—the wild-type
and mutant ANK proteins were present on the oocyte
plasma membrane (ﬁg. 2D).
The inability of the C331R and G389R mutant proteins
to transport PPi, coupled with the dominant inheritance
of CMD, suggested that these two allelesmight act as dom-
inant negatives. Oocytes co-injected with wild-type and
mutant (C331R or G389R) cRNA exhibited signiﬁcantly
less uptake than did those injected with wild-type cRNA
alone (ﬁg. 2C). When coexpressed with the wild-type ANK
protein, the CMD-mutant proteins (C331R and G389R)
did not grossly affect ANK surface expression (ﬁg. 2D).
In Vivo Test of Human Disease Alleles
Transgenic mice were generated to test the effect of the
human mutations on ANK activity in vivo and to attempt
to recapitulate CCAL2 and CMD in mice. A mouse BAC
that was shown elsewhere to rescue the ank phenotype3
was modiﬁed by homologous recombination in bacteria37
to incorporate the appropriate base-pair mutations in the
Ank ORF. One CCAL2 BAC (BAC-AnkM48T), one CMD BAC
(BAC-AnkG389R), and one unmodiﬁed BAC were used to es-
tablishmultiple transgenic founders from independent in-
tegrations. Founders were bred to/Anknull mice for 2 gen-
erations (ﬁg. 3A), and transgenic lines were screened by
RT-PCR performed on multiple organs to identify those
that expressed the transgene (ﬁg. 3B and 3C and data not
shown).
To test the function of the M48T (CCAL2) and G389R
(CMD) ANK-mutant proteins in vivo, we used rescue of
the Ank null phenotype as an assay. When wild-type ANK
is provided by a transgenic BAC in ank-mutant mice, the
severe joint-fusion phenotype is greatly reduced or elim-
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Figure 2. PPi-transport assay with disease-causing Ank alleles. A, Oocytes expressing mutant Ank alleles were assayed for PPi uptake
over a 20-min period at near-saturating conditions (7 mM). Note that oocytes expressing either of the CCAL2 proteins (P5T or M48T)
exhibited wild-type uptake, whereas oocytes expressing the truncated ank protein (E440X) or either of the CMD proteins (C331R or
G389R) exhibited little to no uptake. An asterisk (*) indicates versus wild-type control; ). B, Apparent Km measurementsP .0005 n 3
for wild-type (WT) and CCAL2 proteins. Neither mutant was signiﬁcantly different from wild-type controls tested in parallel ( fornp 4
each mutant allele; for wild type). ND p not determined. C, Oocytes were co-injected with a 1:1 ratio of wild-type and mutantnp 8
Ank cRNA. Both CMD proteins (C331R and G389R) had a statistically signiﬁcant dominant negative effect, although the effect from
C331R was stronger. Numbers on the X-axis are ng of cRNA injected. Values from water-injected oocytes were subtracted from experimental
values. A single asterisk (*) indicates ; a double asterisk (**) indicates versus wild-type control; ). D, SurfaceP ! .05 P ! .003 np 4
biotinylation assays for plasma membrane localization of wild-type and mutant ANK proteins when expressed in Xenopus oocytes. All
of the tested variants were detected at the surface, with the exception of the truncated ank protein, which served as a control for
antibody speciﬁcity. The C331R mutant protein showed decreased surface expression compared with wild type. When the dominant
negative CMD mutant proteins (C331R and G389R) were coexpressed with wild-type ANK, they did not grossly affect its surface expression.
A smaller band is seen in some lanes, but its presence was inconsistent in multiple trials, and we were unable to determine its nature.
PDI localizes to the endoplasmic reticulum and served as a negative control for surface expression.
inated.3 We recently showed that Ank null mice exhibit
the same phenotype as do ank mice.25 Therefore, if a mu-
tant ANK protein provided by a modiﬁed BAC transgene
is active (transports PPi), no joint-fusion phenotype should
be observed in transgenic Ank null mice. If the introduced
mutant ANK protein is inactive, these mice should instead
exhibit joint fusion.
For all tested BAC clones (wild type, M48T, and G389R),
those lines that did not express the transgene, as assessed
by RT-PCR, also did not rescue the joint phenotypes (zero
of ﬁve lines tested). For the wild-type and M48T BAC
clones, most lines that expressed the transgene showed
signiﬁcant rescue of joint phenotypes (three of four lines
tested).
Control experiments showed that expression of the wild-
type mouse BAC signiﬁcantly reduced the severity of joint
defects in Ank-knockout mice, as reported elsewhere for
animals homozygous for the classical Ankank allele.3 Partial
rescue included delayed onset (by at least 2 wk in two
mice and at least 2 mo in ﬁve mice) and full rescue of
some joints accompanied by complete fusion of other
joints. Despite both individual and regional variation, the
phenotypes of all eight transgenic Ank null mice were
much less severe than were those of nontransgenic null
littermates.
Two of three transgenic lines that expressed the M48T
CCAL2 allele, as assessed by RT-PCR, also showed signif-
icant rescue of Ank null phenotypes. For BAC-AnkM48T line
1, expression of the M48T transgene did not rescue the
Ank null phenotype (zero of six mice). However, expres-
sion of this CCAL2-mutant protein in line 2 conferred a
partial rescue reminiscent of the rescue observed using
wild-type ANK. This included a delay of disease onset that
eventually led to the fusion of some joints but left other
joints unaffected (9 of 12 mice). In all nine cases of partial
rescue for line 2, the phenotype of transgenic Ank null
mice was much less severe than was the phenotype of
nontransgenic null littermates. Finally, BAC-AnkM48T line
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Figure 3. Transgenic expression of Ank disease alleles in mice. A, Breeding strategy. BACs were modiﬁed by homologous recombination
in bacteria and were used to generate transgenic founders. Founders were crossed for 2 generations with /Anknull mice. B–C, Analysis
of RT-PCR products from /Anknull;BAC and control /Anknull;BAC mice. In panel B, direct sequencing conﬁrmed the expression of
the AnkM48T allele, which is derived from a TrC bp change (arrow). In panel C, restriction digests conﬁrmed the expression of the AnkG389R
allele (arrow), which does not contain an FokI site. The wild-type allele was detected in all cases. D, mCT-derived volumetric reconstructions
of digits 2–4 of the right forepaw at age 6 wk. Whereas the AnkM48T allele rescued the Ank null phenotype in two of three transgenic
lines, the AnkG389R allele did not rescue in any of the four lines. As a control, the wild-type ANK protein expressed from an unmodiﬁed
BAC rescued the Ank mutant phenotypes in four of four transgenic lines3 (and data not shown).
3 exhibited full rescue, since Ank null mice expressing the
M48T protein still showed no signs of crystal formation,
joint fusion, or immobility by age 6 mo (16 of 16 mice),
a time when their nontransgenic Ank null littermateswere
completely immobile (ﬁg. 3D).
In contrast to results with both wild-type ANK and
M48T (CCAL2) BACs, introduction of a BAC carrying the
G389R (CMD) mutation failed to rescue the joint-fusion
phenotype of Ank null mutants. A total of 52 Ank null
animals carrying the G389R BAC were tested, including
6, 9, 15, and 22 from four independent transgenic lines.
Lack of rescue was not due to failure to express the G389R
allele, since RT-PCR analysis conﬁrmed expression of the
altered allele (ﬁg. 3C). Interestingly, these in vivo rescue
data parallel the in vitro oocyte experiments in which
CCAL2-mutant proteins stimulated wild-type levels of PPi
transport and the CMD mutant proteins were unable to
stimulate PPi transport.
Knee Analysis of BAC-AnkM48T Transgenic Mice
To test for late-onset phenotypes in animals with the
CCAL2 mutation, mice aged 6 mo or 1.5 years with the
genotypes (1) /, (2) /;BAC-AnkM48T, (3)/Anknull, and
(4) /Anknull;BAC-AnkM48T were analyzed by mCT for the
presence of abnormal crystal content in the knee, a major
load-bearing joint of the animal and a common site of
CPPD crystal deposition in humans. There were no signs
of ectopic crystals or osteoarthritis in any of the mice
scanned at age 6mo. By age 1.5 years, somemice exhibited
signs of osteoarthritis in the knee, including ectopic crys-
tal formation, osteophyte formation, and enlarged/ex-
panded menisci. However, each of these features also oc-
curred spontaneously in control animals, and we could
detect no signiﬁcant increase in incidence that was at-
tributable to the presence of the BAC-AnkM48T transgene.
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This analysis was performed using both AnkM48T lines that
rescued the Ank null phenotype.
Skull and Femur Analysis of BAC-AnkG389R Transgenic
and Ank Null Mice
Because CMD affects skull and femur morphology in hu-
mans, we used mCT to evaluate the skulls and femurs of
mice with the genotypes (1) /, (2) /;BAC-AnkG389R,
(3) /Anknull, (4) /Anknull;BAC-AnkG389R, (5) Anknull/Anknull,
and (6) Anknull/Anknull;BAC-AnkG389R (ﬁg. 4A). Formostmea-
surements, no signiﬁcant differences were seen between
groups that differed only in the presence or absence of
the BAC transgene. However, numerous important differ-
ences were observed between wild-type and Ank null an-
imals, and many of these differences suggest that reduced
function of ANK in mice can recapitulate some of the
phenotypic defects in CMD. Skulls of Ank null mice, aged
6 mo, were 0.71 mm narrower (7.1% difference; ;Pp .013
per genotype) and 1.22 mm shorter (4.7% differ-np 6
ence; ; per genotype) than were skulls ofPp .001 np 6
wild-type mice. None of the scanned skulls exhibited oc-
ular hypertelorism, paranasal bossing, obliteration of the
nasal sinuses, or mandibular prognathism, all of which
are characteristic features of CMD in humans. However,
the foramen magnum of Ank null mice was signiﬁcantly
reduced in size compared with that of wild-type mice at
age 6 mo (ﬁg. 4A). A narrow foramen magnum is a doc-
umented feature of CMD in human patients.49,50
Like the skulls of patients with CMD, skulls of Ank null
mice also contained thicker and denser bones than those
of /Anknull or wild-type mice. A thickness value was cal-
culated for each pixel from mCT skull scans (see the “Ma-
terial and Methods” section). These data were used to gen-
erate (1) a spatially resolved and color-coded thickness
map for each skull and (2) a histogram depicting the num-
ber of pixels with each thickness value (ﬁg. 4B). Although
marked sclerosis throughout the skull was not observed,
this analysis revealed discrete anatomical regions that were
thicker in the skulls of Ank null mice than in heterozygous
or wild-type mice. The differences were also present in
skulls from 6-wk-old mice (e.g., 0.3 mm3 thickness counts
of 76, 84, and 139 thousand pixels in /, /Anknull, and
Anknull/Anknull mice, respectively).
Skulls from Ank null mice showed increased thickness
in the basio-occipital bone, the tympanic bulla, and the
petrous portion of the temporal bone, which houses the
middle-ear bones and cochlea of the animal’s hearing ap-
paratus (ﬁg. 4B and data not shown). Two-dimensional
“slice” images revealed fusions between the middle-ear
bones (ﬁg. 4C and 4D). These fusions were already present
in Ank null mice at age 6 wk, before the metacarpal-pha-
lange joints of the hindpaw had ankylosed. Hearing loss
due to hyperostosis, ﬁxation, and fusion of the middle-
ear bones is a well-documented feature of CMD, as are
increased bone in the petrous portion of the temporal
bone and increased bone in the cranial base.49–53
One of the most recognizable features of CMD in hu-
mans is a ﬂaring or “clubbing” of the distal metaphysis
of the femur, accompanied by a thin overlying cortex. A
morphometric analysis revealed that the femurs of Ank
null mice were slightly shorter and thinner than those of
wild-type mice, but no signiﬁcant ﬂaring at the distal end
of the femur was associated with any of the analyzed ge-
notypes. Femurs were then evaluated for other features
associated with bone remodeling. At the ages of 6 wk and
6mo, Anknull/Anknull mice exhibited a reduced ratio of bone
volume to tissue volume (BV:TV) in the metaphysis (ﬁg.
5B). This was accompanied by a thin overlying cortex at
age 6 wk (ﬁg. 5A). Intriguingly, /Anknull;BAC-AnkG389R
mice also displayed a signiﬁcant decrease in BV:TV that
was reminiscent of the decrease noted in Ank null animals
(ﬁg. 5B). Similar defects were not seen in/Anknull animals
without the BAC transgene. Thus, in this sensitized ge-
netic background, the presence of the G389R allele has a
signiﬁcant phenotypic effect on the femur. The AnkG389R
transgenic allele makes/Anknull mice more closely resem-
ble Anknull/Anknull mice, consistent with a dominant neg-
ative effect on the development of phenotypes at this
location.
Discussion
Although ANK activity is known to increase extracellu-
lar levels of PPi, it has remained unclear whether this is
achieved by the translocation of PPi across the plasma
membrane or by indirect effects on intracellular and ex-
tracellular PPi metabolism. We demonstrate here, to our
knowledge for the ﬁrst time, that ANK stimulates the ac-
tual transport of radioactive PPi across the plasma mem-
brane. Our time-course and saturation studies reveal the
basic kinetic parameters, rate, and Km of ANK-stimulated
PPi transport. Both the saturation of transport rate near
10 mM PPi and the measured Km of mM sup-1.33 0.59
port the physiological relevance of ANK activity in the
Xenopus oocyte expression system. The afﬁnity of the
transporter is consistent with a mechanism for maintain-
ing levels of PPi in human synovial ﬂuid at ∼1–10 mM36,
54–57 and with in vitro data that suggest that reduced or
increased PPi levels lead to formation of calcium phos-
phate or calcium PPi dihydrate, respectively.18,20,21,58–61
Because ANK contains multiple transmembrane helices,
is located on the plasma membrane, alters bulk levels of
intracellular and extracellular PPi, and stimulates ﬂux of
radioactive PPi across oocyte membranes, it is likely to
function directly as a PPi transporter3,10,31–33 (and data pre-
sented here). However, it is formally possible that ANK
functions indirectly to regulate the activity of a separate
PPi transporter. Final proof that Ank encodes a transporter
requires puriﬁcation of the ANK protein and reconstitu-
tion in lipidmembranes free of other cellular components.
Nonetheless, the radioactive ﬂux experiments presented
here provide the most direct and sensitive assay yet de-
Figure 4. Skulls from Anknull/Anknull mice, which exhibit CMD-like features. A, Volumetric reconstructions of the foramen magnum from
skulls of wild-type and Ank null mice aged 23 wk. The entryway for the spinal chord was signiﬁcantly smaller in mutant mice (np 6
mice for each genotype). Blackened bars indicate wild type; unblackened bars indicate Ank null; 1, 2, and 3 are the distances represented
by red lines in the wild-type image. B, Ventral view of posterior region of skulls scanned by mCT. The skull images are color-coded for
thickness, and the histogram plots the average number of pixels per thickness value for /, /Anknull, and Anknull/Anknull mice. The
skulls of mice homozygous for the null allele are signiﬁcantly thicker than those of controls. Note that the increase in thickness is not
global but is instead restricted to discrete regions of the skull ( mice for each genotype). C and D, Two dimensional mCT “slice”np 6
images depicting the fusion of middle-ear bones in Ank null mice (m p malleus, i p incus, and s p stapes). A single asterisk (*)
indicates ; a double asterisk (**) indicates ; a triple asterisk (***) indicates versus wild type.P ! .05 P ! .01 P ! .001
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Figure 5. mCT analysis of the femur. A, Volumetric reconstructions of cortical and cancellous bone from the metaphysis of wild-type
and mutant distal femurs. The cortex from Ank null mice was slightly thinner but similar in shape, whereas the cancellous bone was
sparse compared with wild type. B, Quantiﬁed values for images in panel A for mice euthanized at age 6 wk and 6 mo. Ank null mice
exhibited decreased metaphyseal cortical thickness at age 6 wk but not at age 6 mo. In contrast, these mice exhibited a decreased
ratio of bone:tissue volume (BV:TV) relative to wild type in the metaphyseal cancellous bone at both age 6 wk and age 6 mo. Note
that the presence of BAC-AnkG389R had no affect on wild-type or Ank null mice. However, this BAC had a signiﬁcant dominant negative
effect on the cancellous region of /Anknull mice at age 6 mo. A single asterisk (*) indicates ; a double asterisk (**) indicatesP ! .05
; a triple asterisk (***) indicates versus wild-type control; a pound sign (#) indicates for BAC versus BAC;P ! .01 P ! .001 P ! .01
the number of mice analyzed is indicated at the base of each bar.
veloped for ANK-stimulated transport and for testing the
activity of mutant ANK proteins.
CCAL2 Mutations
Previous studies showed that CCAL2 alleles retain at least
wild-type levels of activity.10 However, conﬂicting results
have been described for these and other CCAL2 muta-
tions, including reported loss of activity for both P5T and
M48T.31 Surprisingly, the same mutation (M48T) tested by
two groups scored as indistinguishable from wild type in
one case and as complete loss of function in the other. In
both cases, assessment of ANK activity relied on measure-
ments of bulk PPi levels surrounding and inside cells after
several days of culture. Because PPi is rapidly degraded
and is generated as a by-product of numerous metabolic
reactions—including RNA and DNA elongation, tRNA syn-
thesis, and fatty-acid activation—the reported changes in
PPi levels after cell transfection may be the result of in-
direct mechanisms that are variable across different cell
types and different culture conditions.We report here that
both tested human CCAL2 mutations (P5T and M48T)
retain substantial PPi-transport activity in radiotracer ﬂux
experiments, which take place over minutes instead of
days. Both mutant proteins had an apparent afﬁnity and
a rate similar to that of the wild-type protein.
In addition, we tested the functional consequences of
ANK mutations in vivo for the ﬁrst time. The transgenic
M48T-mutant ANK protein was able to rescue the joint-
mobility defects of Ank null mice, conﬁrming the func-
tional activity of the CCAL2 alleles measured in the ﬂux
experiments. These results are consistent with previous
models that CCAL2 is the result of subtle changes in ANK
activity,10,34 which may result from small changes in pro-
tein function undetected by our assay or by alterations in
mRNA or protein stability or in the way ANK interacts
with other proteins.
We favor the ANK gain-of-function hypothesis, in which
the CCAL2 mutations lead to higher steady-state concen-
trations of PPi in the joint space. This is supported by both
the increased levels of PPi in synovial ﬂuid and the devel-
opment of CPPD crystal deposits in patients with CCAL2.
However, we have not yet been able to demonstrate ac-
tivities higher than wild type, using either cell-culture or
oocyte assays. In addition, the AnkM48T allele restores nor-
mal joint function in Ank null animals but does not stim-
ulate overall increase in mineralization, as typically seen
in patients with CCAL2. Although humans and mice are
very similar in most metabolic pathways, signiﬁcant dif-
ferences do exist.62 To the best of our knowledge, theCPPD
crystal type has never been reported in mice, and it is
possible that mice do not possess the appropriate chemical
environment for CPPD-crystal formation. In addition, hu-
man patients with CCAL2 are unaffected until age 30–40
years, perhaps because of wear and tear or particular types
of mechanical stress. It may be impossible to mimic these
conditions in the 2-year life span of a mouse. Even hu-
mans with hypophosphatasia (MIM 146300, 241510, and
241500), who experience a lifetime of systemically in-
creased PPi levels, generally do not develop CPPD joint
crystals until adulthood.63 It is also possible that the BAC
we used does not contain the cis-acting regulatory se-
quences necessary for the induction of CCAL2. However,
this is unlikely, because the BAC does contain the proper
sequences to drive Ank expression in the joints and to
rescue the null phenotype3 (and data presented here). De-
spite the absence of CCAL2 phenotypes in transgenic
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Figure 6. Range of mutations and phenotypes at the ANKH locus.
The nature of mutations is suggested on the basis of biochemical
assays and functional tests in transgenic mice. HA p hydroxy-
apatite crystal deposits; CPPD p CPPD crystal deposits; Dom neg
p dominant negative; neomorph p neomorphic allele; eye dist
p distance between the eyes.
mice, the combination of both in vitro and in vivo results
clearly shows that CCAL2 alleles retain substantial activity
and are not loss-of-function mutations.
CMD Mutations
It has been proposed elsewhere that CMD alleles are ei-
ther “leaky” gain-of-function,8 loss-of-function, or per-
haps dominant negativemutations.11 Our in vitro ﬂux and
in vivo transgenic rescue experiments show that, in con-
trast to the CCAL2mutations, the CMDmutations (C331R
and G389R) abolish or greatly reduce ANK PPi-transport
activity. Co-injection experiments in frog oocytes (ﬁg. 2C)
and genetic tests in heterozygous Ank mice (ﬁg. 5B) also
suggest that CMD alleles have some dominant negative
effects.
Previous data from heterozygous null mutations inmice
and 5p deletions in human patients with cri du chat syn-
drome (MIM 123450) suggest that loss of one copy of the
ANKH gene does not produce the phenotype of either
CCAL2 or CMD.25,64 ANK activity may need to be reduced
to below 50% of normal to produce ectopic mineraliza-
tion, which would explain the limited mutation spectrum
of CMD alleles. CMD mutations are strikingly clustered
within the ANK protein rather than being distributed
throughout the protein, as might be expected if simple
loss of ANK function were sufﬁcient to produce CMDphe-
notypes.8,11 The mechanism for the dominant negative
effect of CMD alleles is currently not clear. Although the
C331R mutant exhibits reduced surface expression, the
wild-type, CCAL2, and CMD forms of the ANK protein all
translocate to the cell surface when expressed alone (ﬁg.
2D). When the C331R or G389R mutants are coexpressed
in the same cell with wild-type protein, substantial levels
of ANK are detected at the cell surface, whereas transport
activity is markedly reduced (ﬁg. 2C and 2D). This sug-
gests that intracellular trapping is not the primary or only
mechanism leading to reduced activity. It is possible that
CMD alleles have additional effects on the speciﬁcity of
ANK-transport activity, formation of ANK homomulti-
mers, or interactions with other proteins that participate
in PPi metabolism, such as ENPP1.3,33,65,66
If CMD is caused by the dominant negative inhibition
of ANK activity, then some CMD phenotypes might be
expected in animals with !50% of normal ANK activity,
including Anknull/Anknull mice. A careful mCT examination
of bone thickness and density conﬁrmed several previ-
ously unappreciated phenotypes in Ank null mice that do
resemble defects seen in patients with CMD, including
increased thickness of a subset of skull bones, fusion of
the middle-ear bones, and narrowing of the foramenmag-
num. Flaring of the distal femur, which is seen in humans,
was not detected in mice, perhaps because of differences
in the shape and mechanical loading of femurs in bipedal
versus quadrapedal animals. Interestingly, we did detect a
reduction in cancellous bone volume in the metaphysis
of the femur of Ank null mice. The ﬂared metaphysis of
patients with CMD is often described as radiolucent or
nonsclerotic,49–51,67 and it has been suggested that CMD
may affect the proper trabeculation of the metaphyses.11
The loss of bone at this location in patients with CMD
and Ank null mice is in contrast to the increased bone else-
where in the skeleton. This may be explained by the ex-
pression of Ank in the growth plate and the reported role
of ANK in chondrocyte hypertrophy and mineralization.68
The recent knockout of the Ank gene and the current
experiments on CCAL2 and CMD alleles provide a work-
ing model for interpreting the phenotypic effects of dif-
ferent ANK mutations25 (ﬁg. 6). Animals with two copies
of the Ank gene have normal skulls, limbs, and joints. Loss
of one copy of the gene is also compatible with normal
bone, presumably because either 50% or 100% of ANK
activity provides sufﬁcient PPi transport to inhibit ectopic
hydroxyapatite mineral formation. The dominant nega-
tive activity of CMD alleles leads to a further reduction in
ANK activity below the 50% level. At this point, some
bone phenotypes begin to occur, including thickening of
skull bones and narrowing of foramina. Complete loss of
ANK activity triggers widespread ectopic hydroxyapatite
deposition, leading to severe mineralization of joints and
articular cartilage.
The dual role of PPi as both an inhibitor of hydroxy-
apatite formation and stimulator of calcium PPi mineral
deposition leads to a different form of crystal pathology
in patients with CCAL2. Unlike CMD alleles, CCAL2 al-
leles show signiﬁcant PPi-transport activity in vitro and
signiﬁcant rescuing activity in transgenic mice. Slight gain-
of-function mutations in ANK activity may predispose to
precipitation of CPPD crystals, a phenotype seen in pa-
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tients with CCAL2 by the 3rd or 4th decade of life. Syn-
ovial ﬂuid from the knees of up to 60%of patients (average
age 70 years) before arthroplasty contains CPPD and/or
hydroxyapatite crystals,69 and recent reports show ele-
vated levels of ANKH expression in cartilage samples from
patients with sporadic CPPD deposition.66,70 Given the
sensitivity of crystal deposition to total levels of ANK ac-
tivity, modulation of this pathwaymay be a useful clinical
target for controlling susceptibility to common mineral-
deposition diseases.
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